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Studies in a multitude of models including cell culture, animal and clinical studies demonstrate that citrus-derived ﬂavonoids
have therapeutic potential to attenuate dyslipidemia, correct hyperinsulinemia and hyperglycemia, and reduce atherosclerosis.
Emerging evidence suggests the metabolic regulators, PPARα and PGC1α, are targets of the citrus ﬂavonoids, and their activation
may be at least partially responsible for mediating their metabolic eﬀects. Molecular studies will add signiﬁcantly to the concept of
these ﬂavonoids as viable and promising therapeutic agents to treat the dysregulation of lipid homeostasis, metabolic disease, and
its cardiovascular complications.
1.Introduction
Metabolic syndrome is a clustering of risk factors including
dyslipidemia, hypertension, insulin resistance, and visceral
obesity for the development of type 2 diabetes mellitus
and premature atherosclerosis [1–3]. While pharmacological
agents have been successfully used to target major risk
factors including hypertension, plasma cholesterol, and
blood sugar, data collected from 1994–2005 suggest that the
prevalence of hypertension, diabetes and obesity and the
number of people diagnosed with CVD are increasing in
all groups of Canadians [4]. The increased risk was most
dramatic in the youngest group studied (aged 12–34 years
old). In light of the increasing prevalence of metabolic
dysregulation, new therapies are required. In the search for
new targets and interventions to improve underlying risk
factors and prevent the complications of atherosclerosis,
attention has turned to nontraditional therapies includ-
ing a group of naturally-occurring compounds known as
ﬂavonoids.
2. Flavonoids andMetabolic Disease
Flavonoids are abundant in the human diet as several
thousands have been identiﬁed in a large variety of beverages
and foods [5]. They have been classiﬁed based on their
structural variation and degree of oxidation [5]. Flavonoid
intake is inversely associated with coronary heart disease as
men in the highest tertile of ﬂavonoid intake experience the
lowest relative risk of mortality from coronary artery disease
[6]. An inverse relationship between ﬂavonoid consumption
and many risk factors for heart disease [7] including lower
blood pressure and improved ﬂow mediated dilatation [8],
improved weight management [9], and improved dyslipi-
demia [8, 10] has also been established, suggesting that
ﬂavonoids have multiple targets. In human studies, wide
variability has been observed in the eﬀects of ﬂavonoid-
rich foods on these markers of cardiovascular disease
risk [8]. Understanding the speciﬁc targets responsible for
risk reduction is diﬃcult to delineate in such a complex
system. Therefore, recent attention has turned to puriﬁed2 PPAR Research
ﬂavonoids and the examination of their pharmacological
properties.
Many studies have estimated ﬂavonoid intake, and
while the family of ﬂavan-3-ols including catechins found
in tea and chocolate often make up the majority [11],
the ﬂavanones also contribute signiﬁcantly to total daily
intake [12]. The citrus ﬂavanones hesperitin and naringenin
are members of this family (reviewed in [13]). Naringin,
the glycoside form of naringenin found in citrus fruits,
is hydrolyzed by intestinal microﬂora to the ﬂavanone
naringenin. Making up a smaller percentage of total intake
is the class of ﬂavones which contains the polymethoxylated
polyphenols nobiletin and tangeretin, two ﬂavonoids found
abundantly in oranges and tangerines [12]. Administration
of grapefruit or orange juice to hypercholesterolemic casein-
fedrabbitsreducedlowdensitylipoproteincholesterol(LDL-
C) and hepatic lipid accumulation suggesting components
of citrus may have lipid lowering properties [10]. In rats
with streptozotocin- (STZ-) induced diabetes, i.p. injection
of naringenin decreased blood glucose and improved dys-
lipidemia [14]. These early data suggested that citrus-derived
ﬂavonoids may improve metabolic health in patients with
insulin resistance and prevent diabetes and CVD.
While a direct relationship has not been clearly estab-
lished, a common thread linking many of the features
of the metabolic syndrome includes the aberrant tissue
deposition of lipid including cholesterol, ceramides, and
triglycerides [15]. The dyslipidemia of metabolic syndrome,
which is characterized by an overproduction of hepatic very
low density lipoproteins (VLDL-) and low high density
lipoproteins (HDL-) cholesterol [16], is thought to be a
signiﬁcant contributor to enhanced tissue lipid deposi-
tion. Triglyceride (TG) formation is the primary method
of metabolic fuel storage for most species [17] and the
formation of TG can protect cells from fatty acid (FA)
overload and subsequent lipotoxicity [15]. Ectopic lipid
accumulation has been described in many tissues including
the heart, arteries, liver, muscle, adipose tissue, and pancreas
and has been linked to the dysfunction of these tissues
in models of insulin resistance and metabolic syndrome
[15, 18]. Therefore, one mechanism by which ﬂavonoids
have been described to prevent metabolic dysregulation is to
limit ectopic lipid accumulation and stimulate fatty acid and
glucose utilization.
3. PPARα-MediatedRegulation ofMetabolism
Peroxisome proliferator-activated receptor alpha (PPARα)
is a member of the family of nuclear hormone receptors
which function as ligand activated transcription factors,
with a signature type II zinc ﬁnger DNA binding motif,
to control the expression of speciﬁc genes involved in fatty
acid utilization [19, 20]( Figure 1). Liver, muscle, kidney,
and brown adipose tissue express high levels of PPARα
[20, 21]. The endogenous ligands for PPARα activation
include fatty acids and their metabolites [22]. PPARs control
expression of genes by partnering with RXR and binding
to peroxisome proliferator response elements (PPREs) in
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Figure 1: Regulation of gene expression by peroxisome
proliferator-activated receptors. The nuclear hormone receptor
PPARα induces transcription through formation of a heterodimer
with the retinoic X receptor and binding to peroxisome proliferator
response elements (most are direct repeats with one intervening
nucleotide) in the promoter of genes involved in fatty acid
oxidation. PGC1α is an important PPARαcoactivator in tissuesthat
undergo extensive oxidative metabolism and induce mitochondrial
expansion.
the promoter of target genes, ultimately resulting in the
stimulation of FA oxidation. In mice, receptor agonists cause
proliferation of peroxisomes which serve to oxidize long
chain fatty acids and detoxify xenobiotic compounds [23].
PPARα is an activator of genes involved in β-oxidation
including carnitine palmitoyl transferase 1 (CPT1α) and
acyl-CoA oxidase (ACOX). In the liver, fatty acid oxidation
is primarily regulated by the level of CPT1 [24]. CPT1α
expression is controlled by a complex of transcription factors
including PPARγ-coactivator 1 α (PGC1α)a n dP P A R α [24].
CPT1 is found on the outer surface of the mitochondria and
transportsfattyacidsintothemitochondriabytheformation
of an acyl-carnitine molecule. Upon entry into the inner
side of the mitochondrial membrane, CPT2 removes the
carnitine, reforming acyl-CoA [24].
Dynamic regulation of fatty acid oxidation is provided
by interaction between acetyl-CoA carboxylase (ACC), a
member of the fatty acid synthesis pathway, and CPT1,
through the intermediate malonyl-CoA. When malonyl-
CoA levels are high, they allosterically inhibit CPT1 and
de novo lipogenesis continues. When the cell experiences
a drop in malonyl-CoA, ACC is inhibited and fatty acid
oxidation is stimulated [25, 26]. In liver-speciﬁc Fas−/−
mice signiﬁcant increases in malonyl-CoA were observed to
inhibit CPT1α resulting in hepatic steatosis [27]. Recently,
adenovirus-mediated hepatic expression of a permanently
active mutant form of Cpt1α in high-fat fed obese mice,
resulted in increased hepatic FA oxidation, thereby reducing
hepatic TG content and ameliorating insulin resistance [28].PPAR Research 3
These studies highlight the importance of CPT1α-regulated
fatty acid oxidation in maintaining lipid balance in the cell.
Many nuclear receptor cofactors exist which provide
additional control of gene expression [29]. In the liver, coac-
tivators important for induction of PPARα-mediated gene
transcription and regulation of lipid metabolism include
PGC1α.P G C 1 α regulates a number of hepatic metabolic
pathways, including gluconeogenesis, mitochondrial expan-
sion, and FA oxidation [30]. Once bound to a transcription
factor, PGC1α allows the interaction of histone modi-
ﬁers, the transcriptional initiation complex and DNA [31]
(Figure 1). Similar to PPARα, hepatic PGC1α is induced
by fasting, through a cAMP response element [32]. Mice
with hepatic-speciﬁc knockout of Pgc1α accumulate liver
TG, due to impaired β-oxidation, and enhanced SREBP1c-
stimulated FA and TG synthesis [33, 34]. It is known that
PGC1α increases genes involved in mitochondrial expansion
through induction of the nuclear respiratory factors [31].
Furthermore, PGC1α interacts with and coactivates PPARα
to transcriptionally regulate the genes involved in FA oxida-
tion and increase palmitate utilization rates [29].
PPARα is most active in response to a drop in blood
glucose, whether by fasting or by exercise [20]. In addition to
replenishing ATP, the process of FA oxidation also provides
the reducing cofactors required for gluconeogenesis and can
induce the utilization of FA for the production of ketone
bodies [35]. Mice with whole body deﬁciency of PPARα have
decreased capacity for the oxidation FA including palmitic
acid [36] and elevated total- and HDL-cholesterol levels
[23], after a 48h fast. Furthermore, Pparα−/− mice exhibit
hypoglycemia, signiﬁcant lipid accumulation in the liver,
increased circulating nonesteriﬁed fatty acids, and decreased
ketogenesis [37].
Pharmacological activators of PPARα, including the
ﬁbratefamilyofdrugs,havedemonstratedeﬃcacyforreduc-
ing plasma TG and raising HDL in dyslipidemic patients
and are often used in patients with insulin resistance. A
recent meta-analysis of trials involving hypertriglyceridemic
patients demonstrated that ﬁbrates reduce vascular events
[38], suggesting a renewed interest in the activation of
PPARα to prevent CVD in select patients with dyslipidemia.
4. Regulation of Lipid Metabolismand
Correction of Dyslipidemiaby
CitrusFlavonoids
Like ﬁbrates, many citrus-derived ﬂavonoids exhibit lipid-
loweringproperties.Theconsumptionof1-2grapefruits/day
signiﬁcantly reduced cholesterol and triglyceride in hyper-
cholesterolemic patients suﬀering from coronary artery
disease [39, 40]. In a clinical trial involving hyper-
cholesterolemic patients, the citrus ﬂavonoid naringin
(400mg/day) was shown to reduce LDL-cholesterol by
17% and triglycerides by 14% [41]. However, in other
recent human trials, capsules of hesperitin (800mg/day) or
naringin (500mg/day) produced no lipid lowering beneﬁt in
moderately hypercholesterolemic individuals [42].
In more mechanistic studies, it was demonstrated in cul-
tured hepatoma cells that naringenin reduces CE availability
for lipoprotein assembly and secretion through inhibition
of ACAT and MTP activities [43, 44]. However, subsequent
studies established that the reduction in CE accumulation
within the lumen of the endoplasmic reticulum (ER) did not
mediate the naringenin-induced inhibition of apolipopro-
tein B100 (apoB100) assembly. Instead it was the reduction
in TG accumulation within the ER lumen by inhibition
of MTP that primarily facilitated the naringenin-mediated
decrease in apoB secretion [43, 44]. In detailed pulse-
chase studies, naringenin decreased apoB100 secretion from
HepG2cellseveninthepresenceofoleate,throughenhanced
apoB degradation [44]. Studies in rat liver McARH7777
cells, transfected with constructs containing human apoB
of various lengths, revealed that naringenin only inhibited
the secretion of apoB-containing particles that required
lipidation, whereas shorter length apoB constructs, which
require minimal lipidation for secretion, were unaﬀected
[43]. These in vitro ﬁndings suggest that naringenin limits
TG availability for apoB secretion.
Metabolic studies in Ldlr−/− mice demonstrated that
a western type diet stimulated the production rate of
VLDL-TG and apoB100 when compared with chow-fed
mice [45]. Supplementation of the western diet with 3%
naringenin completely prevented the overproduction of
apoB100 and TG, supporting the previous in vitro data that
naringenin prevents VLDL-apoB100 secretion. The pattern
of hepatic lipid accumulation mirrored TG secretion, as
hepatic TG was increased 2-fold in western-fed animals
compared to chow-fed mice and levels were signiﬁcantly
reduced by naringenin. Signiﬁcant increases in the hepatic
mRNA expression of Srebf1c (5-fold) and increased TG
synthesis (1.3-fold) were related to the signiﬁcant hyperin-
sulinemia induced by the western diet. These parameters
were all normalized by 3% naringenin. In concert with
the decrease in insulin-stimulated lipogenesis, naringenin
stimulated hepatic expression of Cpt1α,A c o x , and fatty
acid β-oxidation to prevent hepatic TG accumulation [45].
In ICR rats fed 1% naringenin for 21 days, signiﬁcantly
increased hepatic levels of mRNA coding for enzymes
involved in peroxisomal and omega fatty acid oxidation were
observed [46]. Although a pharmacological dose was used
in these studies, concentrations of dietary naringenin as low
as 0.6% have been reported to lower hepatic triglyceride
levels in rats fed a high-fat diet; however, these eﬀects
were not observed in rats fed a high carbohydrate diet
[47].
In high-fat fed Ldlr−/− mice, addition of nobiletin
(0.1% and 0.3%w/w) resulted in a dramatic reduction in
both hepatic and intestinal TG accumulation, attenuation
of VLDL-TG secretion, normalization of insulin sensitivity
and conferred an almost complete resistance to obesity,
without eﬀect on caloric consumption or fat absorption
[48]. These studies indicate that prevention of the hepatic
lipid load by nobiletin limits the availability lipid for
hepatic storage, lipoprotein secretion and deposition in
peripheral tissues. Others have demonstrated in hamsters fed
a semipuriﬁed diet that supplementation with mixtures of4 PPAR Research
1% polymethoxylated ﬂavonoids, containing tangeretin and
nobiletin, lowered plasma concentrations of both TG and
cholesterol and reduced hepatic TG [49].
Similar to naringenin, addition of nobiletin to a western
diet increased hepatic β-oxidation, contributing to reduced
hepatic TG, decreased VLDL secretion and the correction of
insulin resistance. Both naringenin and nobiletin increased
hepatic Pgc1α mRNA, which coincided with increased Cpt1α
mRNA, mitochondrial DNA and hepatic FA oxidation
[45]. However, nobiletin did not increase mRNA of Acox
[48]. Studies in male ICR rats fed a diet containing 1%
naringenin for 21 days demonstrated increased mRNA levels
of enzymes involved in peroxisomal fatty acid oxidation
which resulted in a signiﬁcant increase (+56%) in the rate
of peroxisomal fatty acid oxidation compared with controls
[50].
The molecular signals for the induction of FA oxidation
in liver by naringenin or nobiletin have not been identi-
ﬁed. In HepG2 cells, using concentrations of naringenin
and nobiletin that inhibited apoB100 secretion by 50–
70% (100μM naringenin, 10μM nobiletin), we observed
upregulation of PPARα target genes including Cpt1α,b u t
not activation of a luciferase promoter containing three
PPRE elements suggesting these ﬂavonoids do not function
as direct PPARα activators [45, 48]. Furthermore, induction
of Pparα mRNA expression and increased liver weight,
characteristic of PPARα activators in mice (ﬁbrates), did not
occur with naringenin [45] or nobiletin [48].
In contrast, naringenin has been reported to stimulate
PPRE promoter activity in U-2OS cells, a human osteosar-
coma cell line [51]. Also, in the human liver cell line
Huh-7, naringenin, at relatively high doses, induced PPRE
activity 17% at 150μMa n da c t i v a t e daP P A R α-GAL4 fusion
protein by 24% at 240μM. These authors also observed
increased transcription of enzymes involved in fatty acid
utilizationincludingPgc1α,Acox,andUcp1 [52].Inacellfree
system, naringenin did not increase the binding of PGC1α
to PPARα but did signiﬁcantly increase Pgc1α mRNA by
14-fold in the Huh7 hepatocyte cell line [52]. These data
suggest that at high concentrations, these ﬂavonoids may
directly activate PPARα. However, in human studies oral
administration of naringenin in capsules (135–199mg) or
ingestion of grapefruit juice (single dose, 8mL of juice/kg)
leads to much lower plasma naringenin concentrations (6.0–
7.3μmol/L) [53, 54] than concentrations used in vitro (50–
240μM), suggesting suboptimal doses for clinical eﬃcacy.
Therefore, further experimentation should focus on more
closely linking in vivo observations with in vitro mechanistic
studies.
Tangeretin also has been shown to increase hepatic
protein concentrations of PPARα which was associated with
increased fatty acid oxidation and a reduction in liver
triglyceride [55]. Addition of a mixture of polymethoxy-
lated ﬂavonoids (1:1; tangeretin:nobiletin) to the diet of
fructose-fedGoldenSyrianhamstersreducedplasmaTGand
prevented lipid accumulation in liver and heart, but not
in muscle [56]. These authors demonstrated a signiﬁcant
increase in hepatic PPARα protein expression, suggesting
that an increase in fatty acid oxidation leads to the observed
attenuation of hepatic steatosis and improved dyslipidemia
[56].
5. Amelioration of Insulin Resistance by
CitrusFlavonoids
Skeletal muscle is the major tissue responsible for insulin-
mediatedglucoseuptake.InstateswhereFAﬂuxisincreased,
as in insulin resistance, both the oxidation of glucose and its
conversiontoglycogenareimpaired[57].Myocytesandhep-
atocytes can become overwhelmed by lipid, with storage and
oxidation pathways at capacity, allowing FA intermediates
such as ceramide and diacylglycerol to accumulate [58, 59].
FA metabolites activate serine kinase pathways including
JNK and PLC which can lead to inhibition of the insulin
receptor [60], preventing its activation and downstream
signaling. Without activation of PI3K, GLUT4 does not
undergo translocation and fusion with the plasma mem-
brane resulting in impaired glucose uptake and utilization
[61]. Pparα−/− mice fed a high-fat diet have increased TG in
adipose and muscle, but do not develop insulin resistance,
suggesting that PPARα-stimulated oxidation of ectopic lipid
in peripheral tissues, including muscle, increases the cellular
concentration of lipid derivatives which contribute to insulin
resistance [35]. Therefore, treatments that promote glucose
utilization by preventing cellular accumulation of TG- and
FA-derived lipid metabolites may substantially improve
peripheral insulin resistance and ameliorate impaired glu-
cose uptake.
Interestingly, in western diet-fed Ldlr−/− mice, narin-
genin did not stimulate fatty acid oxidation in muscle nor
were any changes observed in the expression of genes linked
to fatty acid oxidation, such as Cpt1β, Ucp1,a n dUcp3 [45].
Instead, naringenin inhibited SREBP1c-mediated de novo
lipogenesis and promoted glucose uptake. These results sug-
gestthatnaringenindoesnotactdirectlyonmuscle.Reduced
muscle lipid accumulation and improved glucose utilization
in this model is consequent to attenuated de novo lipogenesis
and decreased uptake of lipoprotein-derived lipid, the latter
a consequence of decreased VLDL secretion. By increasing
hepatic FA oxidation, naringenin permits glucose to be
utilized by peripheral tissues, including muscle, resulting
in the prevention of both lipid accumulation and insulin
resistance (Figure 2) .T h ep r o t e c t i v ee ﬀect of naringenin
in preventing the metabolic disturbances associated with
high-fat feeding was also observed in wild-type C57BL/6J
mice. In this model, naringenin signiﬁcantly reduced plasma
and hepatic lipids, normalized glucose tolerance and insulin
sensitivityandpreventedobesitywhencomparedtowestern-
fed mice, although the time course for the preventative eﬀect
was signiﬁcantly longer than that required for Ldlr−/− mice
[45].
6.CitrusFlavonoidsasAntioxidantsandFree
RadicalScavengers
Flavonoids, as dictated by their structure, are reducing
agents and can serve as eﬃcient chelators of transitionPPAR Research 5
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Figure 2: Potential mechanisms for the reduction in risk factors for atherosclerosis by ﬂavonoids. Both in vitro and in vivo data suggest
that citrus ﬂavonoids decrease macrophage uptake of oxidized LDL and macrophage CE accumulation and improve dyslipidemia. While the
completemechanismshavenotbeenfullydeﬁned,thenuclearhormonereceptorsPPARαandPGC1αrepresentimportantmoleculartargets.
The improvement in dyslipidemia can be linked to decreased VLDL secretion as hepatic lipid availability for storage or VLDL secretion is
decreased as a consequence of PPAR-stimulated fatty acid oxidation. The oxidation of fatty acids by liver prevents ectopic lipid accumulation
and improves both insulin sensitivity and glucose tolerance. Arrows indicate change in response to ﬂavonoid treatment.
metals involved in cellular oxidation reactions [62, 63]. The
association between ﬂavonoids, including citrus ﬂavonoids,
and metabolic disorders and atherosclerosis has been linked
to their antioxidant properties and to a reduction in
oxidative stress. In vitro, naringin is an eﬃcient free radical
scavenger, but has limited antioxidant activity in mouse
liver homogenates [64]. In STZ diabetic rats, naringin
(40mg/kg/day) was shown to prevent diabetic neurogenic
pain through its prevention of free radical formation and
antioxidant activities in the sciatic nerve [65]. In mice fed
a high-fat diet, naringin (0.02%) improved indices of insulin
resistance,whichwasattributed,inpart,toimprovedhepatic
enzymes involved in free radical scavenging and antioxidant
activities [66]. Naringenin has also been demonstrated to
have antioxidant properties. Naringenin (0.02%) increased
hepatic glutathione peroxidase and superoxide dismutase
activities and decreased hepatic and plasma TBARS [67].
In diabetic rats, naringenin (50mg/kg/day) signiﬁcantly
increased enzymes with antioxidant activity in pancreas
and plasma and decreased serum activities of ALT, AST,
ALP, and LDH [68]. However, it is not known if narin-
genin or naringin has direct eﬀects on the expression of
activities of these enzymes, or if the eﬀects are secondary
to the ﬂavonoid-induced correction of dysregulated lipid
metabolism.
7. Prevention of Atherosclerosis by
CitrusFlavonoids
In addition to correction of dyslipidemia and glucose intol-
erance, treatment with nobiletin (0.3% w/w) or naringenin
(3%w/w) in Ldlr−/− mice for 6 months led to a marked
reduction in the progression of atherosclerosis [48, 69].
In rabbits fed a high-cholesterol diet, supplementation of
0.1% naringin or 0.05% naringenin for 8 weeks decreased
aortic fatty streak area when compared to controls [70]. In
wild-type mice fed a high-fat/high-cholesterol/0.5% cholic
acid in a cocoa butter diet, 0.02% naringin reduced plaque
progressionby41%,butnobeneﬁcialeﬀectsofnaringinwere
observed in ApoE−/− mice fed the same diet [71]. Naringin
signiﬁcantly reduced soluble E-selectin and soluble inter-cell
adhesion molecule-1 in these mice [71]. Molecular studies
have demonstrated that incubation of lipopolysaccharide-
treated RAW-264.7 macrophages with naringenin, dose-
dependently decreased the production of tumour necrosis
factor (TNFα) and monocyte chemoattractant protein 1
(MCP-1) [72]. Nobiletin and its derivatives have been
shown to reduce the expression and activity of macrophage
scavenger receptors [73] including CD36 and SRAI/II and
decrease the uptake of acetylated LDL [74]. These studies
suggest that in addition to decreased exposure of the vessel6 PPAR Research
wall to increased plasma lipoproteins, ﬂavonoids directly
decrease both lipoprotein uptake and the inﬂammatory
response within macrophages of the arterial intima. PPARα
activation has also been demonstrated to reduce monocyte
recruitment to the vascular wall by downregulating vascular
cell adhesion molecule-1, MCP-1 and interleukin-6 [75].
Ligands of PPARα have also been demonstrated to reduce
foam cell formation by reducing lipid uptake and increasing
lipid eﬄux [76]. Fenoﬁbrate has been demonstrated to
reduce foam cell formation and slow the progression of
atherosclerosis in mice [77, 78], suggesting that some of the
eﬀectsof citrusﬂavonoids maybemediated throughPPARα-
stimulated pathways.
8.Additional Targets of CitrusFlavonoids
While some preliminary human studies suggest metabolic
beneﬁt [39–41], an enhanced understanding of the molec-
ular targets of natural polyphenols is required in order to
identify the main mechanism of action. While PPARα has
emerged as a potential target, numerous studies have also
identiﬁed PPARγ as a prospective target. In diabetic male
Wistar albino rats fed a high-fat diet, naringin increased
PPARγ protein expression in liver. Interestingly, the authors
also observed a decrease in the expression of LXR and
SREBP1c and a reduction in hepatic steatosis [79]. It has also
been reported that naringenin at 80μM, activated a PPARγ-
GAL4 construct up to 57% [52]. In 3T3-L1 adipocytes,
both naringenin and hesperitin upregulated PPARγ at both
80μM and 160μM, which resulted in a signiﬁcant increase
in the expression of adiponectin [51]. Nobiletin (10μM)
stimulatesdiﬀerentiationofST-13preadipocytesintomature
adipocytes and signiﬁcantly increases the production of
adiponectin protein [80].
9. Summary
Collectively, these studies add to the growing body of evi-
dence that citrus ﬂavonoids have marked lipid and lipopro-
tein lowering potential and demonstrate that naringenin
and nobiletin reduce hepatic lipid accumulation and prevent
lipoproteinoverproduction,normalizeglucosetoleranceand
insulin sensitivity and slow the progression of atherosclerosis
(Figure 2). These beneﬁcial metabolic eﬀects are mediated,
in part, by the metabolic regulators, PPARα,P P A R γ,a n d
PGC1α, although further studies are required to fully reveal
the interaction of these ﬂavonoids with upstream mediators
in this pathway.
Abbreviations
ACOX: Acyl-CoA oxidase
ACAT: Acyl-CoA:cholesterol acyltransferase
apoB100: Apolipoprotein B100
CPT1: Carnitine palmitoyl transferase 1
CE: Cholesteryl ester
CVD: Cardiovascular disease
DGAT1/2: Diacylglycerol acyl transferase 1/2
FA: Fatty acid
FAS: Fatty acid synthase
FC: Free cholesterol
HDL: High density lipoprotein
LDL: Low density lipoprotein
MCP: Monocyte chemmoattractant protein 1
MTP: Microsomal triglyceride transfer protein
PI3K: Phosphoinositide-3-kinase
PPAR: Peroxisome proliferator-activated receptor
PPRE: PPAR response element
PGC1α: Peroxisome proliferator-activated receptor
gamma coactivator 1α
SREBP1c: Sterol regulatory element binding protein
TG: Triglyceride
TNFα: Tumour necrosis factor
VLDL: Very low density lipoprotein
UCP-1: Uncoupling protein 1.
Conﬂict of Interests
The authors declare that they have no ﬁnancial conﬂicts of
interests.
Acknowledgments
Research from the authors’ laboratory was funded by Grants
from the Heart and Stroke Foundation of Ontario (T-
7007 and PG-5967) and the Canadian Institutes of Health
Research (MT-8014).
References
[1] A. Garg and S. M. Haﬀner, “Insulin resistance and atheroscle-
rosis: an overview,” Diabetes Care, vol. 19, no. 3, article 274,
1996.
[2] H. N. Ginsberg and L. S. Huang, “The insulin resistance syn-
drome: impact on lipoprotein metebolism and atherothrom-
bosis,” Journal of Cardiovascular Risk, vol. 7, no. 5, pp. 325–
331, 2000.
[3] H. N. Ginsberg, Y. L. Zhang, and A. Hernandez-Ono,
“Metabolicsyndrome:focusondyslipidemia,”Obesity,vol.14,
supplement 1, pp. 41S–49S, 2006.
[4] D. S. Lee, M. Chiu, D. G. Manuel et al., “Trends in risk
factors for cardiovascular disease in Canada: temporal, socio-
demographicandgeographicfactors,”CMAJ,vol.181,no.3-4,
pp. E55–E66, 2009.
[5] A. Scalbert and G. Williamson, “Dietary intake and bioavail-
ability of polyphenols,” Journal of Nutrition, vol. 130, no. 8,
supplement, pp. 2073S–2085S, 2000.
[6] M. G. L. Hertog, E. J. M. Feskens, P. C. H. Hollman, M. B.
Katan, and D. Kromhout, “Dietary antioxidant ﬂavonoids and
risk of coronary heart disease: the Zutphen Elderly Study,” The
Lancet, vol. 342, no. 8878, pp. 1007–1011, 1993.
[7] L. A. Bazzano, “The high cost of not consuming fruits and
vegetables,” Journal of the American Dietetic Association, vol.
106, no. 9, pp. 1364–1368, 2006.
[8] L. Hooper, P. A. Kroon, E. B. Rimm et al., “Flavonoids,
ﬂavonoid-rich foods, and cardiovascular risk: a meta-analysis
of randomized controlled trials,” American Journal of Clinical
Nutrition, vol. 88, no. 1, pp. 38–50, 2008.PPAR Research 7
[9] B. C. Tohill, J. Seymour, M. Serdula, L. Kettel-Khan, and
B. J. Rolls, “What epidemiologic studies tell us about the
relationship between fruit and vegetable consumption and
body weight,” Nutrition Reviews, vol. 62, no. 10, pp. 365–374,
2004.
[10] E. M. Kurowska, J. D. Spence, J. Jordan et al., “HDL-
cholesterol-raising eﬀect of orange juice in subjects with
hypercholesterolemia,” American Journal of Clinical Nutrition,
vol. 72, no. 5, pp. 1095–1100, 2000.
[11] K. C. Ock, J. C. Sang, and W. O. Song, “Estimated dietary
ﬂavonoid intake and major food sources of U.S. adults,”
Journal of Nutrition, vol. 137, no. 5, pp. 1244–1252, 2007.
[ 1 2 ]R .Z a m o r a - R o s ,V .K n a z e ,L .L u j´ an-Barroso et al., “Estimated
dietary intakes of ﬂavonols, ﬂavanones and ﬂavones in the
European Prospective Investigation into Cancer and Nutrition
(EPIC) 24 hour dietary recall cohort,” British Journal of
Nutrition, vol. 106, no. 12, pp. 1915–1925, 2011.
[13] E. E. Mulvihill and M. W. Huﬀ, “Antiatherogenic properties of
ﬂavonoids: implications for cardiovascular health,” Canadian
Journal of Cardiology, vol. 26, supplement A, pp. 17A–21A,
2010.
[14] J. S. Choi, T. Yokozawa, and H. Oura, “Improvement of
hyperglycemia and hyperlipemia in streptozotocin-diabetic
rats by a methanolic extract of Prunus davidiana stems and its
main component, prunin,” Planta Medica,v o l .5 7 ,n o .3 ,p p .
208–211, 1991.
[15] R. H. Unger and P. E. Scherer, “Gluttony, sloth and the
metabolic syndrome: a roadmap to lipotoxicity,” Trends in
Endocrinology and Metabolism, vol. 21, no. 6, pp. 345–352,
2010.
[16] S. M. Grundy, “Metabolic syndrome: a multiplex cardiovas-
cular risk factor,” The Journal of Clinical Endocrinology and
Metabolism, vol. 92, no. 2, pp. 399–404, 2007.
[17] C. L. E. Yen, S. J. Stone, S. Koliwad, C. Harris, and R. V. Farese,
“DGAT enzymes and triacylglycerol biosynthesis,” Journal of
Lipid Research, vol. 49, no. 11, pp. 2283–2301, 2008.
[ 1 8 ]R .S .K h a n ,K .D r o s a t o s ,a n dI .J .G o l d b e r g ,“ C r e a t i n ga n d
curing fatty hearts,” Current Opinion in Clinical Nutrition and
Metabolic Care, vol. 13, no. 2, pp. 145–149, 2010.
[19] C. H. Lee, P. Olson, and R. M. Evans, “Minireview: lipid
metabolism, metabolic diseases, and peroxisome proliferator-
activated receptors,” Endocrinology, vol. 144, no. 6, pp. 2201–
2207, 2003.
[20] W. A. Alaynick, “Nuclear receptors, mitochondria and lipid
metabolism,” Mitochondrion, vol. 8, no. 4, pp. 329–337, 2008.
[21] A.L.Bookout,Y.Jeong,M.Downes,R.T.Yu,R.M.Evans,and
D. J. Mangelsdorf, “Anatomical proﬁling of nuclear receptor
expression reveals a hierarchical transcriptional network,”
Cell, vol. 126, no. 4, pp. 789–799, 2006.
[22] B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic
drugs,polyunsaturatedfattyacids,andeicosanoids areligands
for peroxisome proliferator-activated receptors α and δ,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 94, no. 9, pp. 4312–4317, 1997.
[23] J. M. Peters, R. C. Cattley, and F. J. Gonzalez, “Role of PPARα
in the mechanism of action of the nongenotoxic carcinogen
and peroxisome proliferator Wy-14,643,” Carcinogenesis, vol.
18, no. 11, pp. 2029–2033, 1997.
[24] J. P. Bonnefont, F. Djouadi, C. Prip-Buus, S. Gobin, A.
Munnich, and J. Bastin, “Carnitine palmitoyltransferases 1
and2:biochemical,molecularandmedicalaspects,”Molecular
Aspects of Medicine, vol. 25, no. 5-6, pp. 495–520, 2004.
[25] M. Schreurs, F. Kuipers, and F. R. Van Der Leij, “Regulatory
enzymesofmitochondrialβ-oxidationastargetsfortreatment
ofthemetabolicsyndrome,”ObesityReviews,vol.11,no.5,pp.
380–388, 2010.
[26] M. Schreurs, T. H. van Dijk, A. Gerding, R. Havinga, D. J.
Reijngoud, and F. Kuipers, “Soraphen, an inhibitor of the
acetyl-CoA carboxylase system, improves peripheral insulin
sensitivity in mice fed a high-fat diet,” Diabetes, Obesity and
Metabolism, vol. 11, no. 10, pp. 987–991, 2009.
[27] M. V. Chakravarthy, Z. Pan, Y. Zhu et al., “New hepatic fat
activates PPARα to maintain glucose, lipid, and cholesterol
homeostasis,”CellMetabolism,vol.1,no.5,pp.309–322,2005.
[28] J. M. Orellana-Gavald` a, L. Herrero, M. I. Malandrino et al.,
“Molecular therapy for obesity and diabetes based on a long-
term increase in hepatic fatty-acid oxidation,” Hepatology, vol.
53, no. 3, pp. 821–832, 2011.
[29] S. Yu and J. K. Reddy, “Transcription coactivators for
peroxisome proliferator-activated receptors,” Biochimica et
Biophysica Acta, vol. 1771, no. 8, pp. 936–951, 2007.
[30] J. Lin, C. Handschin, and B. M. Spiegelman, “Metabolic con-
trol through the PGC-1 family of transcription coactivators,”
Cell Metabolism, vol. 1, no. 6, pp. 361–370, 2005.
[31] C. Handschin and B. M. Spiegelman, “Peroxisome prolif-
eratoractivated receptor γ coactivator 1 coactivators, energy
homeostasis, and metabolism,” Endocrine Reviews, vol. 27, no.
7, pp. 728–735, 2006.
[32] S. Herzig, F. Long, U. S. Jhala et al., “CREB regulates hepatic
gluconeogenesis through the coactivator PGC-1,” Nature, vol.
413, no. 6852, pp. 179–183, 2001.
[33] T. C. Leone, J. J. Lehman, B. N. Finck et al., “PGC-1alpha deﬁ-
ciency causes multi-system energy metabolic derangements:
muscle dysfunction, abnormal weight control and hepatic
steatosis,” PLoS Biology, vol. 3, no. 4, article e101, 2005.
[34] J. L. Estall, M. Kahn, M. P. Cooper et al., “Sensitivity of lipid
metabolismandinsulinsignalingtogeneticalterationsinhep-
atic peroxisome proliferator-activated receptor-γ coactivator-
1α expression,” Diabetes, vol. 58, no. 7, pp. 1499–1508, 2009.
[35] M. Guerre-Millo, C. Rouault, P. Poulain et al., “PPAR-α-
null mice are protected from high-fat diet-induced insulin
resistance,” Diabetes, vol. 50, no. 12, pp. 2809–2814, 2001.
[36] T. Aoyama, J. M. Peters, N. Iritani et al., “Altered constitutive
expression of fatty acid-metabolizing enzymes in mice lacking
the peroxisome proliferator-activated receptor α (PPARα),”
The Journal of Biological Chemistry, vol. 273, no. 10, pp. 5678–
5684, 1998.
[37] T. C. Leone, C. J. Weinheimer, and D. P. Kelly, “A critical role
for the peroxisome proliferator-activated receptor α (PPARα)
in the cellular fasting response: the PPARα-null mouse as a
model of fatty acid oxidation disorders,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 96, no. 13, pp. 7473–7478, 1999.
[38] M. Lee, J. L. Saver, A. Towﬁghi, J. Chow, and B. Ovbi-
agele, “Eﬃcacy of ﬁbrates for cardiovascular risk reduction
in persons with atherogenic dyslipidemia: a meta-analysis,”
Atherosclerosis, vol. 217, no. 2, pp. 492–498, 2011.
[39] S. Gorinstein, A. Caspi, I. Libman, E. Katrich, H. T. Lerner,
andS.Trakhtenberg,“Preventiveeﬀectsofdietssupplemented
with sweetie fruits in hypercholesterolemic patients suﬀering
fromcoronaryarterydisease,”PreventiveMedicine,vol.38,no.
6, pp. 841–847, 2004.
[40] S. Gorinstein, A. Caspi, I. Libman et al., “Red grapefruit
positively inﬂuences serum triglyceride level in patients suf-
fering from coronary atherosclerosis: studies in vitro and in
humans,” Journal of Agricultural and Food Chemistry, vol. 54,
no. 5, pp. 1887–1892, 2006.8 PPAR Research
[41] U.J.Jung,H.J.Kim,J.S.Leeetal.,“Naringinsupplementation
lowers plasma lipids and enhances erythrocyte antioxidant
enzyme activities in hypercholesterolemic subjects,” Clinical
Nutrition, vol. 22, no. 6, pp. 561–568, 2003.
[42] I. Demonty, Y. Lin, Y. E. M. P. Zebregs et al., “The citrus
ﬂavonoids hesperidin and naringin do not aﬀect serum
cholesterol in moderately hypercholesterolemic men and
women,” Journal of Nutrition, vol. 140, no. 9, pp. 1615–1620,
2010.
[43] N.M.Borradaile,L.E.DeDreu,P.H.R.Barrett,C.D.Behrsin,
and M. W. Huﬀ, “Hepatocyte ApoB-containing lipoprotein
secretion is decreased by the grapefruit ﬂavonoid, naringenin,
via inhibition of MTP-mediated microsomal triglyceride
accumulation,” Biochemistry, vol. 42, no. 5, pp. 1283–1291,
2003.
[44] N. M. Borradaile, L. E. De Dreu, P. H. R. Barrett, and M.
W. Huﬀ, “Inhibition of hepatocyte apoB secretion by narin-
genin: enhanced rapid intracellular degradation independent
of reduced microsomal cholesteryl esters,” Journal of Lipid
Research, vol. 43, no. 9, pp. 1544–1554, 2002.
[45] E. E. Mulvihill, E. M. Allister, B. G. Sutherland et al.,
“Naringenin prevents dyslipidemia, apolipoprotein B over-
production, and hyperinsulinemia in LDL receptor-null mice
with diet-induced insulin resistance,” Diabetes, vol. 58, no. 10,
pp. 2198–2210, 2009.
[46] D. T. T. Huong, Y. Takahashi, and T. Ide, “Activity and mRNA
levels of enzymes involved in hepatic fatty acid oxidation in
mice fed citrus ﬂavonoids,” Nutrition, vol. 22, no. 5, pp. 546–
552, 2006.
[47] N. Wood, “Hepatolipidemic eﬀects of naringenin in high
cornstarch- versus high coconut oil-fed rats,” Journal of
Medicinal Food, vol. 7, no. 3, pp. 315–319, 2004.
[48] E. E. Mulvihill, J. M. Assini, J. K. Lee et al., “Nobiletin attenu-
ates VLDL overproduction, dyslipidemia, and atherosclerosis
inmicewithdiet-inducedinsulinresistance,”Diabetes,vol.60,
no. 5, pp. 1446–1457, 2011.
[49] E.M.KurowskaandJ.A.Manthey,“Hypolipidemiceﬀectsand
absorption of citrus polymethoxylated ﬂavones in hamsters
with diet-induced hypercholesterolemia,” Journal of Agricul-
turalandFoodChemistry,vol.52,no.10,pp.2879–2886,2004.
[ 5 0 ]U .J .J u n g ,M .K .L e e ,Y .B .P a r k ,M .A .K a n g ,a n dM .S .
Choi, “Eﬀect of citrus ﬂavonoids on lipid metabolism and
glucose-regulating enzyme mRNA levels in type-2 diabetic
mice,” International Journal of Biochemistry and Cell Biology,
vol. 38, no. 7, pp. 1134–1145, 2006.
[51] L.Liu,S.Shan,K.Zhang,Z.Q.Ning,X.P.Lu,andY.Y.Cheng,
“Naringenin and hesperetin, two ﬂavonoids derived from
Citrus aurantium up-regulate transcription of adiponectin,”
Phytotherapy Research, vol. 22, no. 10, pp. 1400–1403, 2008.
[52] J.Goldwasser,P.Y.Cohen,E.Yang,P.Balaguer,M.L.Yarmush,
and Y. Nahmias, “Transcriptional regulation of human and
rat hepatic lipid metabolism by the grapefruit ﬂavonoid
naringenin:roleofPPARα,PP ARγ andLXRα,” PLoSONE,vol.
5, no. 8, Article ID e12399, 2010.
[53] I. Erlund, E. Meririnne, G. Alfthan, and A. Aro, “Human
nutrition and metabolism: plasma kinetics and urinary excre-
tion of the ﬂavanones naringenin and hesperetin in humans
after ingestion of orange juice and grapefruit juice,” Journal of
Nutrition, vol. 131, no. 2, pp. 235–241, 2001.
[54] F. I. Kanaze, M. I. Bounartzi, M. Georgarakis, and I. Niopas,
“Pharmacokinetics of the citrus ﬂavanone aglycones hes-
peretin and naringenin after single oral administration in
human subjects,” European Journal of Clinical Nutrition, vol.
61, no. 4, pp. 472–477, 2007.
[ 5 5 ]E .M .K u r o w s k a ,J .A .M a n t h e y ,A .C a s a s c h i ,a n dA .G .
Theriault, “Modulation of HepG2 cell net apolipoprotein B
secretionbythecitruspolymethoxyﬂavonetangeretin,” Lipids,
vol. 39, no. 2, pp. 143–151, 2004.
[56] R. W. Li, A. G. Theriault, K. Au et al., “Citrus polymethoxy-
lated ﬂavones improve lipid and glucose homeostasis and
modulate adipocytokines in fructose-induced insulin resistant
hamsters,” Life Sciences, vol. 79, no. 4, pp. 365–373, 2006.
[57] S. R. Kashyap, R. Belfort, R. Berria et al., “Discordant eﬀects
of a chronic physiological increase in plasma FFA on insulin
signaling in healthy subjects with or without a family history
of type 2 diabetes,” American Journal of Physiology, vol. 287,
no. 3, pp. E537–E546, 2004.
[ 5 8 ]M .A d i e l s ,M .R .T a s k i n e n ,a n dJ .B o r ´ en, “Fatty liver, insulin
resistance, and dyslipidemia,” Current Diabetes Reports, vol. 8,
no. 1, pp. 60–64, 2008.
[59] T. R. Koves, J. R. Ussher, R. C. Noland et al., “Mitochondrial
overload and incomplete fatty acid oxidation contribute to
skeletal muscle insulin resistance,” Cell Metabolism, vol. 7, no.
1, pp. 45–56, 2008.
[60] S. Schenk, M. Saberi, and J. M. Olefsky, “Insulin sensitivity:
modulation by nutrients and inﬂammation,” The Journal of
Clinical Investigation, vol. 118, no. 9, pp. 2992–3002, 2008.
[61] A. Klip, “The many ways to regulate glucose transporter 4,”
Applied Physiology, Nutrition and Metabolism,v o l .3 4 ,n o .3 ,
pp. 481–487, 2009.
[62] R. R. Huxley and H. A. W. Neil, “The relation between dietary
ﬂavonol intake and coronary heart disease mortality: a meta-
analysis of prospective cohort studies,” European Journal of
Clinical Nutrition, vol. 57, no. 8, pp. 904–908, 2003.
[ 6 3 ]S .A .A h e r n ea n dN .M .O ’ B r i e n ,“ M e c h a n i s mo fp r o t e c -
tion by the ﬂavonoids, quercetin and rutin, against tert-
butylhydroperoxide- and menadione-induced DNA single
strand breaks in Caco-2 cells,” Free Radical Biology and
Medicine, vol. 29, no. 6, pp. 507–514, 2000.
[64] C.Yuting,Z.Rongliang,J.Zhongjian,andJ.Yong,“Flavonoids
as superoxide scavengers and antioxidants,” Free Radical
Biology and Medicine, vol. 9, no. 1, pp. 19–21, 1990.
[65] A. D. Kandhare, K. S. Raygude, P. Ghosh, A. E. Ghule,
a n dS .L .B o d h a n k a r ,“ N e u r o p r o t e c t i v ee ﬀect of naringin
by modulation of endogenous biomarkers in streptozotocin
induced painful diabetic neuropathy,” Fitoterapia. In press.
[66] P. Pu, D.-M. Gao, S. Mohamed et al., “Naringin ameliorates
metabolic syndrome by activating AMP-activated protein
kinaseinmicefedahigh-fatdiet,”ArchivesofBiochemistryand
Biophysics, vol. 518, no. 1, pp. 61–70, 2012.
[67] S. M. Jeon, H. K. Kim, H. J. Kim et al., “Hypocholesterolemic
and antioxidative eﬀects of naringenin and its two metabolites
in high-cholesterol fed rats,” Translational Research, vol. 149,
no. 1, pp. 15–21, 2007.
[68] T. Annadurai, A. R. Muralidharan, T. Joseph, M. J. Hsu, P.
A. Thomas, and P. Geraldine, “Antihyperglycemic and antiox-
idant eﬀects of a ﬂavanone, naringenin, in streptozotocin-
nicotinamide-induced experimental diabetic rats,” Journal of
Physiology and Biochemistry. In press.
[69] E. E. Mulvihill, J. M. Assini, B. G. Sutherland et al., “Narin-
genin decreases progression of atherosclerosis by improving
dyslipidemia in high-fat-fed low-density lipoprotein receptor-
null mice,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 30, no. 4, pp. 742–748, 2010.
[70] C. H. Lee, T. S. Jeong, Y. K. Choi et al., “Anti-atherogenic
eﬀect of citrus ﬂavonoids, naringin and naringenin, associated
with hepatic ACAT and aortic VCAM-1 and MCP-1 in highPPAR Research 9
cholesterol-fed rabbits,” Biochemical and Biophysical Research
Communications, vol. 284, no. 3, pp. 681–688, 2001.
[71] A. Chanet, D. Milenkovic, C. Deval et al., “Naringin, the
major grapefruit ﬂavonoid, speciﬁcally aﬀects atherosclerosis
development in diet-induced hypercholesterolemia in mice,”
JournalofNutritionalBiochemistry,vol.23,no.5,pp.469–477,
2012.
[72] S. Hirai, Y. I. Kim, T. Goto et al., “Inhibitory eﬀect of narin-
genin chalcone on inﬂammatory changes in the interaction
between adipocytes and macrophages,” Life Sciences, vol. 81,
no. 16, pp. 1272–1279, 2007.
[73] J. H. Yen, C. Y. Weng, S. Li et al., “Citrus ﬂavonoid 5-
demethylnobiletinsuppressesscavengerreceptorexpressionin
THP-1 cells and alters lipid homeostasis in HepG2 liver cells,”
Molecular Nutrition and Food Research, vol. 55, no. 5, pp. 733–
748, 2011.
[74] S. C. Whitman, E. M. Kurowska, J. A. Manthey, and A.
Daugherty,“Nobiletin,acitrusﬂavonoidisolatedfromtanger-
ines, selectively inhibits class A scavenger receptor-mediated
metabolism of acetylated LDL by mouse macrophages,”
Atherosclerosis, vol. 178, no. 1, pp. 25–32, 2005.
[75] V. Pasceri, J. Chang, J. T. Willerson, and E. T. H. Yeh, “Modu-
lation of C-reactive protein-mediated monocyte chemoattrac-
tant protein-1 induction in human endothelial cells by anti-
atherosclerosis drugs,” Circulation, vol. 103, no. 21, pp. 2531–
2534, 2001.
[76] M. Van Bilsen and F. A. Van Nieuwenhoven, “PPARs as
therapeutic targets in cardiovascular disease,” Expert Opinion
on Therapeutic Targets, vol. 14, no. 10, pp. 1029–1045, 2010.
[77] H. Duezt, Y. S. Chao, M. Hernandez et al., “Reduction of
atherosclerosisbytheperoxisomeproliferator-activatedrecep-
tor α agonist fenoﬁbrate in mice,” The Journal of Biological
Chemistry, vol. 277, no. 50, pp. 48051–48057, 2002.
[78] N. Hennuyer, A. Tailleux, G. Torpier et al., “PPARα, but not
PPARγ, activators decrease macrophage-laden atherosclerotic
lesions in a nondiabetic mouse model of mixed dyslipidemia,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no.
9, pp. 1897–1902, 2005.
[79] A. K. Sharma, S. Bharti, S. Ojha et al., “Up-regulation of
PPARγ, heat shock protein-27 and-72 by naringin attenuates
insulin resistance, β-cell dysfunction, hepatic steatosis and
kidney damage in a rat model of type 2 diabetes,” British
Journal of Nutrition, vol. 106, no. 11, pp. 1713–1723, 2011.
[80] K. Kunimasa, S. Kuranuki, N. Matsuura et al., “Identiﬁcation
of nobiletin, a polymethoxyﬂavonoid, as an enhancer of
adiponectin secretion,” Bioorganic and Medicinal Chemistry
Letters, vol. 19, no. 7, pp. 2062–2064, 2009.